OZEM vs PPH

OZEMCRoundhill GLP-1 & Weight Loss ETF

PPHAVanEck Pharmaceutical ETF

In short

OZEM The whole weight-loss trade in one ticker: roughly 30 stocks covering the drugmakers behind GLP-1 treatments plus the companies expected to benefit as use widens. Broad pharma funds bury this theme. OZEM is built entirely around it.

PPH About two dozen US-listed drugmakers in one ticker, tracking the MVIS US Listed Pharmaceutical 25 Index since 2011. VanEck charges well under the pharma-fund median to run it.

Stated mandate

OZEM The Fund seeks capital appreciation by providing exposure to companies developing pharmaceutical drugs for weight loss and anti-obesity, including GLP-1 treatments, as well as companies expected to benefit from their wider use.

PPH The fund seeks to track, before fees and expenses, the performance of the MVIS US Listed Pharmaceutical 25 Index, which covers companies involved in pharmaceutical research and development, production, marketing, and sales.

Why people hold it

• OZEM The mandate is explicit: companies developing weight-loss and anti-obesity drugs, including GLP-1s, plus firms expected to benefit from wider use. No hedging into general pharma.
• A roughly 30-stock lineup means the theme actually drives the fund, rather than sitting as a small sleeve inside a diversified pharma basket.
• At 0.59%, the fee sits in the same neighborhood as established pharma funds like PJP (0.57%) and FTXH (0.60%), despite the narrower, more specialized mandate.

• PPH Costs 0.36% a year against a 0.57% median for pharma ETFs, undercutting peers like PJP and FTXH.
• Focused by design: the index tracks US-listed pharmaceutical companies (research, production, marketing, sales) rather than the whole health care aisle.vaneck.com
• Trading since 2011, one of the veterans of the pharma shelf, and it sits in the top quartile of its peer group on our review.
• Pays out quarterly, and it is a moderately traded fund, so getting in and out is usually straightforward.

Worth knowing

• OZEM Broad pharma alternatives are cheaper: XPH at 0.35% and PPH at 0.36%. The theme focus here carries a price.
• Thinly traded with a modest asset base, so spreads can be wide. Limit orders are the standard tool for funds in this range.
• Launched in 2024, so the history is short, and a 30-stock single-theme basket swings on trial results and regulatory news at a handful of companies.

• PPH Around 26 holdings. One company's trial result or patent cliff carries real weight in a basket this tight.
• Single-sector health care exposure: drug pricing politics and regulation land on the whole basket at once, with nothing else to cushion it.
• The fee edge over the category is real, but XPH sits at 0.35%, so cost alone is not what separates these two.

Full OZEM profile⁠

Full PPH profile⁠